Introduction {#H1-1-ZOI200110}
============

Benzodiazepines are associated with a number of safety concerns among older adults, including increased risk of falls and hip fracture.^[@zoi200110r1],[@zoi200110r2]^ Although overdose receives less attention as a benzodiazepine-related adverse event, benzodiazepines are the second-most common medication class involved in pharmaceutical overdose deaths,^[@zoi200110r3]^ and overdose deaths that involve benzodiazepines increased more than 6-fold from 1996 through 2014.^[@zoi200110r4]^ More than 75% of benzodiazepine-related deaths involve opioids,^[@zoi200110r3]^ and evidence continues to accumulate that use of benzodiazepines is associated with increased risk of opioid-related overdose and mortality.^[@zoi200110r5],[@zoi200110r6],[@zoi200110r7],[@zoi200110r8]^ Given that older adults experienced the largest absolute increases in opioid-related mortality between 2001 and 2016^[@zoi200110r9]^ and also experience the highest rates of coprescribing of opioids and benzodiazepines,^[@zoi200110r10],[@zoi200110r11]^ benzodiazepine prescribing may be associated with increased opioid-related morbidity and mortality among older adults.

When the Medicare Part D prescription drug coverage program began in 2006, it did not include coverage for benzodiazepines, even though the class is widely prescribed to older adults.^[@zoi200110r12]^ The exclusion was effectively a legacy policy from Medicaid that allowed states to exclude 10 categories of medications from prescription drug coverage, including benzodiazepines.^[@zoi200110r13]^ After Medicare Part D began, there was concern that the lack of benzodiazepine coverage was unduly limiting access to the widely prescribed medication class and causing a financial burden for those who paid out of pocket.^[@zoi200110r14],[@zoi200110r15]^ In response to these concerns, benzodiazepine coverage was added to Medicare Part D in 2013.^[@zoi200110r16]^ However, lowering the barrier to use of benzodiazepines, which were considered inappropriate for most older adults at the time of the policy change,^[@zoi200110r17]^ may have been associated with safety consequences for the millions of older US individuals enrolled in Medicare Part D plans.

In states that have implemented policies that limit benzodiazepine prescribing, fall-related adverse events among older adults have not decreased.^[@zoi200110r18],[@zoi200110r19]^ Although restricting benzodiazepine access has not been associated with injury reduction among older adults, less is known about the consequences associated with abruptly expanding benzodiazepine coverage; lowering the threshold for new prescriptions may have a different association with adverse outcomes than restricting coverage. Furthermore, no studies to our knowledge have examined the association of benzodiazepine coverage with overdose among older adults. In this analysis, we examined the association of fall-related injury and overdose with Medicare's expansion of Part D coverage to include benzodiazepines. Given heightened public attention to opioid prescribing and the potential for harms when opioids and benzodiazepines are coprescribed,^[@zoi200110r5],[@zoi200110r8],[@zoi200110r20]^ we also examined outcomes limited to older adults prescribed opioids. We hypothesized that this nationwide expansion of benzodiazepine coverage would be associated with an increase in the rates of fall-related injury and overdose both overall and among those prescribed opioids.

Methods {#H1-2-ZOI200110}
=======

Study Population {#H2-1-ZOI200110}
----------------

For this ecological study, we used administrative health claims from Optum's deidentified Clinformatics Data Mart Database derived from a large national health insurance company in the US. We created monthly measures of the outcomes using a denominator of all age-eligible (ie, ≥65 years of age) Medicare Advantage (MA) beneficiaries who were enrolled during that month. All older adults in the population had Medicare Part D prescription drug coverage as part of their MA plan. There were no other exclusion criteria. As a comparison group, we used adults 65 years or older in the database with commercial (ie, employer-sponsored) insurance; the prescription plans of these older adults would not have been subject to the benzodiazepine coverage change experienced by MA beneficiaries. The population-level numerators for the 2 analyses were the number of fall-related injury episodes that began in a given month and the number of overdoses. This study was considered not regulated by the Michigan Medicine Institutional Review Board, so informed consent was waived for this analysis of deidentified data. This study followed the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) extension of the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](https://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.^[@zoi200110r21]^

Outcomes {#H2-2-ZOI200110}
--------

We conducted separate analyses for the 2 primary outcomes of interest: fall-related injury rates and overdose rates. We also examined changes in benzodiazepine prescribing after the policy change as an intermediary mechanism for the hypothesized changes in our outcomes of interest.

Episodes of fall-related injury were determined using an algorithm developed and validated using MA claims data.^[@zoi200110r22]^ The algorithm captures single episodes of injury (ie, an ED visit, inpatient stay, and rehabilitation visits that followed a single fall event were counted together as a single episode) across the spectrum of severity from nonfracture injury to hip fracture. If a single injury episode crossed calendar months, it was attributed to the month when the episode began.

Overdoses were captured using *International Classification of Diseases, Ninth Revision, Clinical Modification* diagnoses from emergency department or acute inpatient encounters regardless of intent (codes 960-969 and E850-E858 \[unintentional\], E930-E949 \[adverse drug effect\], E950.0-E950.5 \[self harm\], and E980.0-E980.5 \[undetermined\] based on consensus recommendations from the Injury Surveillance Workgroup^[@zoi200110r23]^).

Population Characteristics {#H2-3-ZOI200110}
--------------------------

We obtained information on patient sex and age along with select additional demographic characteristics (eg, US Census division and race/ethnicity) from demographic data available in the Optum database. For descriptive purposes, we also determined the presence of select clinical conditions for which benzodiazepines may commonly be prescribed in clinical practice, including anxiety disorders, depression, dementia, and insomnia (eTable 1 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}). We stratified these descriptions by insurer type and precoverage and postcoverage period.

Statistical Analysis {#H2-4-ZOI200110}
--------------------

We conducted interrupted time-series analyses to compare the rates of the 2 injury types in the population before and after the Medicare Part D coverage expansion to include benzodiazepines in 2013. For all analyses, the precoverage period was January 1, 2010, to December 31, 2012; the postcoverage period was January 1, 2013, to December 31, 2015. Our models used monthly injury rates as the dependent variable and included a linear time-trend variable, an indicator for the postcoverage period (ie, an indicator for before and after Medicare policy change), and a term for the change in the linear time trend (ie, slope) between the precoverage and postcoverage periods. We did not include a term that tested for an immediate-level shift in outcomes (ie, a change in the model intercept as of the beginning of the postcoverage period in January 2013) because we hypothesized that any change in benzodiazepine prescribing and associated injuries would accumulate over time and not change immediately on January 1, 2013. We constructed analogous models in the comparison group (ie, commercial insurance beneficiaries). To test for the association of the Medicare benzodiazepine coverage policy expansion (ie, a difference in postcoverage rate change between MA beneficiaries and the comparison group), we fit a single model with interactions between group and each term in the interrupted time-series model, specifically reporting the significance of the interaction between groups (MA vs comparison) and the postcoverage rate shift.

Descriptive analyses revealed secular trends in the age distribution of the study population. To guard against confounding on this basis, we stratified analyses by age (65-69, 70-74, 75-79, and ≥80 years). Results of the primary analyses for both outcomes were similar between men and women within each age group; thus, we present primary findings stratified only by age. Models also included monthly fixed effects to account for seasonality of the outcomes. We did not detect any other temporal autocorrelation in the model errors. We used 2-tailed *t* tests to test the statistical significance (α = .05) of the association of benzodiazepine coverage expansion with injury (ie, the rate change between precoverage and postcoverage periods). In addition, given safety concerns about opioid and benzodiazepine coprescribing,^[@zoi200110r24]^ we completed additional analyses that limited the monthly MA population denominator to beneficiaries with 1 day or more of opioid supply in a given month to determine whether results limited to the population prescribed opioids were consistent with those for the overall MA population. Analysis was completed from September 1, 2018, to August 31, 2019.

Results {#H1-3-ZOI200110}
=======

In 2012 (the year before the policy change), women constituted 57.5% of the MA group and 47.4% of the comparison group. A total of 25.8% of individuals in the MA group were aged 65 to 69 years, and 29.3% were 80 years or older (mean \[SD\] age, 75.1 \[6.4\] years); 56.7% of individuals in the comparison group were aged 65 to 69 years, and 15.1% were 80 years or older (mean \[SD\] age, 70.9 \[6.5\] years). There were 4 635 312 individual patients (ie, age-eligible MA beneficiaries), who contributed 156 754 749 person-months from 2010 through 2015. In the comparison group, there were 940 629 individual patients, who contributed 25 104 534 person-months during the same period. Select population characteristics are given in [Table 1](#zoi200110t1){ref-type="table"}. There was a marked increase in benzodiazepine claims among MA beneficiaries beginning in 2013; beneficiaries with 1 day or more of benzodiazepine coverage in a given month increased from approximately 0.5% in 2012 to 6% for much of 2013 (eFigure 1 and eFigure 2 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}).

###### Select Sociodemographic and Clinical Characteristics of Medicare Advantage and Commercially Insured Enrollees (Comparison Group) 65 Years or Older During the Year Before and After the 2013 Medicare Part D Policy Change

  Characteristic                                             Study participants, No. (%)                                       
  ---------------------------------------------------------- ----------------------------- ---------------- ------------------ ----------------
  Age, y                                                                                                                       
  65-69                                                      601 650 (25.8)                250 848 (56.7)   678 930 (24.9)     248 715 (62.9)
  70-74                                                      604 891 (26.0)                80 390 (18.2)    739 907 (27.1)     69 756 (17.6)
  75-79                                                      439 890 (18.9)                44 681 (10.1)    514 435 (18.9)     32 484 (8.2)
  ≥80                                                        683 549 (29.3)                66 797 (15.1)    794 625 (29.1)     44 451 (11.2)
  Sex[^b^](#zoi200110t1n2){ref-type="table-fn"}                                                                                
  Female                                                     1 340 361 (57.5)              209 666 (47.4)   1 577 131 (57.8)   185 400 (46.9)
  Male                                                       989 619 (42.5)                232 706 (52.6)   1 150 766 (42.2)   209 588 (53.0)
  Race/ethnicity[^c^](#zoi200110t1n3){ref-type="table-fn"}                                                                     
  Asian                                                      81 133 (3.5)                  11 047 (2.50)    98 899 (3.6)       11 451 (2.9)
  Black                                                      202 803 (8.7)                 34 072 (7.7)     219 710 (8.1)      30 187 (7.6)
  Hispanic                                                   222 566 (9.6)                 26 677 (6.0)     293 032 (10.7)     28 007 (7.1)
  White                                                      1 544 124 (66.3)              351 031 (79.3)   1 765 941 (64.7)   307 435 (77.8)
  Unknown                                                    66 483 (2.9)                  15 666 (3.5)     80 603 (3.0)       14 259 (3.6)
  US Census division                                                                                                           
  East North Central                                         238 417 (10.2)                65 080 (14.7)    374 688 (13.7)     60 583 (15.3)
  East South Central                                         66 568 (2.9)                  14 337 (3.2)     69 486 (2.6)       14 467 (3.7)
  Middle Atlantic                                            189 933 (8.2)                 29 635 (6.7)     267 295 (9.8)      25 206 (6.4)
  Mountain                                                   268 918 (11.5)                46 873 (10.6)    303 652 (11.1)     47 127 (11.9)
  New England                                                131 578 (5.7)                 16 185 (3.7)     135 140 (5.0)      14 559 (3.7)
  Pacific                                                    471 462 (20.2)                49 625 (11.2)    494 111 (18.1)     45 763 (11.6)
  South Atlantic                                             464 108 (19.9)                103 862 (23.5)   498 123 (18.3)     83 340 (21.1)
  West North Central                                         223 550 (9.6)                 61 263 (0.8)     245 803 (9.0)      46 661 (11.8)
  West South Central                                         231 823 (10.0)                52 514 (13.8)    288 748 (10.6)     52 992 (13.4)
  Unknown                                                    43 623 (1.9)                  3342 (11.9)      50 851 (1.9)       4708 (1.2)
  FPL status                                                                                                                   
  ≤400%                                                      1 875 465 (80.5)              404 595 (91.4)   2 185 833 (88.9)   361 352 (91.4)
  \>400%                                                     84 (0.0)                      49 (0.0)         48 (0.0)           50 (0.0)
  Unknown or missing                                         454 431 (19.5)                38 072 (8.6)     542 016 (19.9)     34 004 (8.6)
  Select diagnoses                                                                                                             
  Any anxiety disorder                                       56 718 (2.4)                  9252 (2.1)       90 219 (3.3)       10 255 (2.6)
  Generalized anxiety disorder                               51 125 (2.2)                  7662 (1.7)       80 149 (2.9)       8334 (2.1)
  PTSD                                                       4138 (0.2)                    1263 (0.3)       8361 (0.3)         1625 (0.4)
  Other anxiety disorders                                    2714 (0.1)                    590 (0.1)        4283 (0.2)         672 (0.2)
  Dementia                                                   264 141 (11.3)                25 259 (5.7)     340 597 (12.5)     20 370 (5.2)
  Depression                                                 343 778 (14.8)                45 850 (10.4)    485 935 (17.8)     44 818 (11.3)
  Seizure disorders                                          20 469 (0.9)                  2802 (0.6)       29 168 (1.1)       2694 (0.7)
  Insomnia                                                   184 869 (7.9)                 26 565 (6.0)     277 749 (10.2)     28 832 (7.3)

Abbreviations: FPL, federal poverty level; PTSD, posttraumatic stress disorder.

Includes enrollees with 1 month or more of enrollment during the indicated calendar year.

Missing for 334 (0.1%) in the 2012 comparison group and 418 (0.1%) in the 2014 comparison group.

Missing for 212 871 (9.1%) in the Medicare Advantage group in 2012, 269 712 (9.9%) in the Medicare Advantage group in 2014, 4223 (1.0%) in the comparison group in 2012, and 4067 (1.0%) in the comparison group in 2014.

Fall-Related Injury {#H2-5-ZOI200110}
-------------------

The baseline rate (ie, the model-predicted rate in January 2010) of fall-related injury was 1.34 per 10 000 person-days (95% CI, 1.31-1.37 per 10 000 person-days) among those aged 65 to 69 years and increased for each age group; the rate was 3.20 per 10 000 person-days (95% CI, 3.15-3.24 per 10 000 person-days) among those 80 years or older ([Table 2](#zoi200110t2){ref-type="table"}). Monthly event rates were similar among the comparison group. During the postcoverage period, the rate of fall-related injury increased for all MA age groups ([Figure 1](#zoi200110f1){ref-type="fig"}). Interaction tests for the rate change between the MA and comparison groups were not significant for the younger age groups (eg, 65-69, 70-74, and 75-79 years). However, for those 80 years or older, the increase in the rate of fall-related injury increased significantly among the MA group compared with the comparison group during the postcoverage period (rate changes for the MA vs comparison groups: 0.12 \[95% CI, 0.07 to 0.17\] vs −0.01 \[95% CI, −0.11 to 0.10\]; *P* = .04 for interaction). The MA analyses stratified by sex yielded similar results for men and women by age group (eTable 2 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}).

###### Interrupted Time-Series Analysis of Monthly Fall-Related Injury Among MA and Commercially Insured Enrollees (Comparison Group) From 2010 to 2015

  Group by age[^a^](#zoi200110t2n1){ref-type="table-fn"}   Before coverage (2010--2012)   After coverage (2013--2015)   Before vs after coverage                                                                                           
  -------------------------------------------------------- ------------------------------ ----------------------------- -------------------------- --------------------- ----------------------- -------- ----------------------- -------- -----
  65-69 y                                                                                                                                                                                                                                  
  MA (n = 3 547 378)                                       1.34 (1.31 to 1.37)            0.00 (−0.01 to 0.02)          .76                        1.38 (1.33 to 1.42)   0.06 (0.03 to 0.09)     .001     0.05 (0.02 to 0.09)     .002     .06
  Comparison (n = 815 567)                                 1.44 (1.41 to 1.48)            −0.02 (−0.04 to 0.00)         .05                        1.40 (1.34 to 1.45)   −0.02 (−0.05 to 0.02)   .33      0.01 (−0.03 to 0.04)    .76      
  70-74 y                                                                                                                                                                                                                                  
  MA (n = 1 668 561)                                       1.50 (1.47 to 1.54)            0.02 (0.00 to 0.04)           .10                        1.56 (1.52 to 1.59)   0.05 (0.02 to 0.07)     \<.001   0.03 (0.00 to 0.06)     .08      .76
  Comparison (n = 211 269)                                 1.62 (1.58 to 1.67)            0.00 (−0.02 to 0.03)          .91                        1.57 (1.50 to 1.64)   0.04 (0.00 to 0.08)     .09      0.04 (−0.01 to 0.09)    .13      
  75-79 y                                                                                                                                                                                                                                  
  MA (n = 1 211 833)                                       1.84 (1.80 to 1.89)            0.03 (0.00 to 0.05)           .07                        1.95 (1.90 to 1.99)   0.06 (0.03 to 0.09)     .001     0.03 (−0.01 to 0.07)    .13      .92
  Comparison (n = 107 596)                                 1.98 (1.91 to 2.06)            −0.03 (−0.07 to 0.02)         .24                        2.02 (1.90 to 2.13)   0.00 (−0.07 to 0.07)    .99      0.03 (−0.06 to 0.11)    .51      
  ≥80 y                                                                                                                                                                                                                                    
  MA (n = 1 439 617)                                       3.20 (3.15 to 3.24)            0.04 (0.01 to 0.06)           .006                       3.30 (3.23 to 3.37)   0.16 (0.11 to 0.20)     \<.001   0.12 (0.07 to 0.17)     \<.001   .04
  Comparison (n = 118 640)                                 3.12 (2.99 to 3.25)            0.04 (−0.04 to 0.11)          .36                        3.51 (3.39 to 3.63)   0.03 (−0.05 to 0.11)    .47      −0.01 (−0.11 to 0.10)   .91      

Abbreviation: MA, Medicare Advantage.

Sample size reflects total number from 2010 to 2015.

Data from the first month of the period.

All rate, rate changes, and *P* values reported were obtained from regression models that included fixed effects for month. The rate presents the change per month in the injury rate.

![Monthly Rates of Fall-Related Injury Among Medicare Advantage and Commercially Insured Enrollees (Comparison Group) From 2010 to 2015\
In models that included fixed effects for month, the interaction term that compared the Medicare Advantage and comparison group rate changes was statistically significant for those 80 years or older (*P* = .04) but not for those aged 65 to 69 years (*P* = .06), 70 to 74 years (*P* = .76), or 75 to 79 years (*P* = .92). Full results are given in [Table 2](#zoi200110t2){ref-type="table"}. The vertical dashed line indicates the time of Medicare Part D benzodiazepine coverage expansion.](jamanetwopen-3-e202051-g001){#zoi200110f1}

Among MA beneficiaries prescribed opioids, the fall rate was markedly higher than in the overall population; however, the precoverage and postcoverage changes were consistent (eTable 3 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}). Similar to the main analysis, the rate of fall-related injury changed after coverage; the precoverage rate was either negative or flat and shifted to an increasing trend in all age groups.

Overdose {#H2-6-ZOI200110}
--------

The baseline rate (ie, the model-predicted rate in January 2010) of overdose was 1.31 per 100 000 person-days (95% CI, 1.22-1.40 per 100 000 person-days) among those aged 65 to 69 years. The rate was highest among those aged 75 to 79 years (1.61 per 10 000 person-days; 95% CI, 1.52-1.70 per 100 000 person-days) ([Table 3](#zoi200110t3){ref-type="table"}). The overdose rate was lower among the comparison group for all ages. During the postcoverage period (2013-2015), the rate of overdose among MA beneficiaries increased for all age groups ([Figure 2](#zoi200110f2){ref-type="fig"}). Compared with the comparison group, the increases in postcoverage overdose rates were statistically significant among those 65 to 69 years old and among those 80 years or older. For those aged 65 to 69 years, the postcoverage rate increased by 0.23 encounters per month (95% CI, 0.17-0.30) vs 0.02 (95% CI, −0.06 to 0.11; *P* \< .001 for interaction) for the comparison group. For those 80 years or older, the postcoverage rate increased by 0.07 encounters per month (95% CI, 0.00-0.14 encounters per month) vs −0.20 (95% CI, −0.35 to −0.05; *P* = .002 for interaction) for the comparison group. The MA analyses stratified by sex yielded similar results for men and women by age group (eTable 4 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}).

###### Interrupted Time-Series Analysis of Monthly Overdose Among MA and Commercially Insured Enrollees (Comparison Group) From 2010 to 2015

  Group by age[^a^](#zoi200110t3n1){ref-type="table-fn"}   Before coverage (2010--2012)   After coverage (2013--2015)   Before vs after coverage change                                                                                            
  -------------------------------------------------------- ------------------------------ ----------------------------- --------------------------------- --------------------- ----------------------- -------- ------------------------ -------- --------
  65-69 y                                                                                                                                                                                                                                          
  MA (n = 3 547 378)                                       1.31 (1.22 to 1.40)            −0.14 (−0.19 to −0.09)        \<.001                            0.86 (0.81 to 0.91)   0.10 (0.06 to 0.13)     \<.001   0.23 (0.17 to 0.30)      \<.001   \<.001
  Comparison (n = 815 567)                                 0.67 (0.57 to 0.78)            −0.02 (−0.08 to 0.04)         .57                               0.63 (0.54 to 0.72)   0.01 (−0.05 to 0.07)    .83      0.02 (−0.06 to 0.11)     .57      
  70-74 y                                                                                                                                                                                                                                          
  MA (n = 1 668 561)                                       1.35 (1.27 to 1.43)            −0.10 (−0.14 to −0.05)        \<.001                            1.02 (0.95 to 1.09)   0.05 (0.01 to 0.10)     .05      0.15 (0.08 to 0.21)      \<.001   .33
  Comparison (n = 211 269)                                 1.00 (0.84 to 1.16)            −0.08 (−0.17 to 0.01)         .11                               0.84 (0.67 to 1.02)   −0.01 (−0.12 to 0.10)   .88      0.07 (−0.07 to 0.21)     .35      
  75-79 y                                                                                                                                                                                                                                          
  MA (n = 1 211 833)                                       1.61 (1.52 to 1.70)            −0.14 (−0.20 to −0.09)        \<.001                            1.10 (1.01 to 1.19)   0.13 (0.07 to 0.19)     \<.001   0.27 (0.19 to 0.35)      \<.001   .46
  Comparison (n = 107 596)                                 1.18 (0.95 to 1.41)            −0.18 (−0.31 to −0.04)        .01                               0.80 (0.54 to 1.05)   0.18 (0.01 to 0.34)     .049     0.36 (0.14 to 0.57)      .002     
  ≥80 y                                                                                                                                                                                                                                            
  MA (n = 1 439 617)                                       1.60 (1.51 to 1.69)            −0.06 (−0.12 to −0.01)        .03                               1.47 (1.41 to 1.53)   0.00 (−0.03 to 0.04)    .87      0.07 (0.00 to 0.14)      .06      .002
  Comparison (n = 118 640)                                 0.91 (0.76 to 1.05)            0.21 (0.13 to 0.29)           \<.001                            1.24 (1.03 to 1.44)   0.01 (−0.12 to 0.14)    .89      −0.20 (−0.35 to −0.05)   .01      

Abbreviation: MA, Medicare Advantage.

Sample size reflects total number from 2010 to 2015.

Data from the first month of the period.

All rate, rate changes, and *P* values reported were obtained from regression models that included fixed effects for month. The rate presents the change per month in the injury rate.

![Monthly Rates of Overdose Among Medicare Advantage and Commercially Insured Enrollees From 2010 to 2015\
In models that included fixed effects for month, the interaction term that compared the Medicare Advantage and comparison group rate changes was statistically significant for those aged 65 to 69 years (*P* \< .001) and those 80 years or older (*P* = .002) and not significant for those age 70 to 74 years (*P* = .33) or 75 to 79 years old (*P* = .49). Full results are given in [Table 3](#zoi200110t3){ref-type="table"}. The vertical dashed line indicates the time of Medicare Part D benzodiazepine coverage expansion.](jamanetwopen-3-e202051-g002){#zoi200110f2}

As with the fall rate, the monthly rate of overdose was markedly higher among beneficiaries prescribed opioids than in the overall population (eTable 5 in the [Supplement](#note-ZOI200110-1-s){ref-type="supplementary-material"}). Similar to the main analysis, the monthly event rate reversed direction from decreasing before coverage to increasing after coverage for those aged 65 to 69 years and 75 to 79 years, with a nonsignificant change among those aged 70 to 74 years.

Discussion {#H1-4-ZOI200110}
==========

In this analysis of 4.6 million MA beneficiaries, we found that, at the population level, expansion of Medicare Part D coverage to include benzodiazepines was associated with increases in benzodiazepine prescription claims for all adults 65 years or older. Our findings suggest that there may have been associated increases in the rate of injury among those aged 65 to 69 years and those 80 years or older. The oldest group experienced increasing rates of both fall-related injury and overdose, whereas among those aged 65 to 69 years, the trend of overdose increased. Findings were not different when the population was limited to older adults who were prescribed opioids.

Although the increase in benzodiazepine claims among MA beneficiaries was increased by 5.5% or more than 10-fold, there were some benzodiazepine claims during the precoverage period (ie, 2010-2012). This finding likely reflects that some MA plans could provide more generous prescription coverage than required by Medicare that included benzodiazepines.^[@zoi200110r25]^ The increase in claims for benzodiazepines likely overestimates the true increase in exposure among older adults because benzodiazepines are available in generic, inexpensive forms; some patients were likely self-paying for benzodiazepine prescriptions before the 2013 coverage change. In an analysis of MA beneficiaries in plans that included prescription drug coverage (including benzodiazepines) before Medicare Part D existed but then excluded benzodiazepines when Medicare Part D began, nearly 75% of MA beneficiaries continued use of benzodiazepines after exclusion by paying out of pocket.^[@zoi200110r15]^ In addition, a recent analysis^[@zoi200110r4]^ of benzodiazepine prescribing trends from 1996 to 2014 using the Medical Expenditure Panel Survey did not demonstrate an increase in prescription benzodiazepine use among respondents 65 years or older in 2013.^[@zoi200110r4]^

We hypothesized that the expansion of coverage would be associated with both types of injury. However, the minimal effect sizes observed align with prior studies^[@zoi200110r18],[@zoi200110r19]^ of policies that restricted benzodiazepine access that did not demonstrate a decrease in injury. One such analysis^[@zoi200110r19]^ that predated Medicare Part D examined hip fracture rates, comparing New York, which instituted a triplicate prescription policy that increased the administrative burden of benzodiazepine prescribing, with New Jersey, which had no such policy. Although there was an immediate 60% reduction in benzodiazepine prescribing in New York, the rate of hip fracture did not decrease compared with that in New Jersey. When Medicare Part D went into effect, some state Medicaid programs provided supplemental coverage of benzodiazepines, whereas other states did not. In an analysis^[@zoi200110r18]^ of dually eligible nursing home residents, benzodiazepine prescribing varied with states' supplemental coverage, but the risk of hip fracture was not lower in states that limited benzodiazepine coverage.^[@zoi200110r18]^

Given these prior analyses, what may account for the limited associations with increased injury in the present analysis? The expansion of Medicare Part D may have had a limited association with overall prevalence of benzodiazepine use among older adults but still would have been associated with a reduced threshold for new use among benzodiazepines-naive patients, particularly those with limited resources. Because those who regularly use benzodiazepines develop physiologic tolerance with repeated exposure,^[@zoi200110r26]^ new users may be particularly susceptible to experiencing an injury when first exposed. A study by Hernandez et al^[@zoi200110r27]^ examining the risk of opioid-related overdose among concurrent opioid and benzodiazepine users suggests that the risk of overdose is highest in the first 90 days of concurrent use and then decreases with each successive time increment.^[@zoi200110r27]^ In addition, some practitioners and patients may have interpreted Medicare's benzodiazepine coverage expansion as an indication that safety risks had been overstated, further lowering the prescribing threshold and leading to prescriptions that practitioners previously avoided because of safety concerns.

We did not anticipate that the change in the overdose rate associated with benzodiazepine coverage would be greater in relative terms than the change in fall-related injury. Safety warnings cautioning against benzodiazepine prescribing in older adults typically focus on the risk of falls.^[@zoi200110r28]^ Their association with overdose other than when prescribed with opioids receives less attention, and unlike for fall-related injury, we are unaware of prior analyses examining the association of benzodiazepine coverage policies with overdose. This lack of attention may be partially because overdose is less common among adults 65 years or older than among younger adults^[@zoi200110r29]^ and is therefore not perceived as a problem. However, a recent analysis^[@zoi200110r9]^ found that the largest relative increases in opioid-related overdose from 2001 to 2016 were among adults aged 55 to 64 years followed by those 65 years or older.

Why might the associations with increased injury have been limited to those aged 65 to 69 years and those 80 years or older in the study population? It is possible that these age groups were vulnerable to the effects of policy change for different reasons. Adverse effects related to benzodiazepines are generally attributed to the role of benzodiazepine as a central nervous system depressant, and older adults are particularly sensitive to these effects.^[@zoi200110r30],[@zoi200110r31]^ An 80-year-old individual may be more sensitive to these effects than a 65-year-old individual. The 65- to 69-year age group includes members of the baby boom cohort, who started turning 65 years of age in 2011. Compared with prior cohorts of older adults (ie, the other age groups in this analysis), baby boomers have higher rates of alcohol use, nonmedical prescription opioid use, and marijuana use,^[@zoi200110r32],[@zoi200110r33],[@zoi200110r34],[@zoi200110r35]^ each of which might be associated with increased susceptibility to benzodiazepine-related injury from a new prescription. By occurring at the height of the opioid overdose crisis, the benzodiazepine coverage expansion potentially exacerbated the risks associated with prescription opioids.

We did not expect the overdose rate to have decreased during the precoverage period; across the US overall, overdose-related deaths among those 65 years or older increased slightly during that time.^[@zoi200110r29]^ Although favorable selection into MA plans has decreased,^[@zoi200110r36],[@zoi200110r37]^ evidence remains that patients with the most complex needs may exit MA,^[@zoi200110r38],[@zoi200110r39]^ and MA patients at the end of life are healthier, more educated, and have fewer functional limitations.^[@zoi200110r40]^ The rate also decreased among the comparison group except among those 80 years or older. The population of adults 65 years or older who continue to maintain employment with employer-sponsored insurance coverage may be healthier and are likely not representative of the general older adult population.

Limitations {#H2-7-ZOI200110}
-----------

This study has limitations. First, the study was limited to MA beneficiaries and not the overall population with Medicare Part D coverage; thus, our findings may not generalize to the entire population of older adults. Second, claims data have limited ability to detect and appropriately classify both of the primary outcomes, which thus may have been limited to events serious enough to require medical attention and to those appropriately coded by practitioners. Third, we cannot account for the true prevalence of benzodiazepine use in the population because patients were likely paying for prescriptions out of pocket or receiving coverage through other sources (eg, Veterans Affairs or Medicaid). Fourth, we did not adjust for patient-level characteristics that may have been changing during this time and potentially contributed to increased falls or overdoses, although our findings remained when restricted to those prescribed opioids.

Conclusions {#H1-5-ZOI200110}
===========

Compared with commercial coverage among similarly aged older adults, Medicare's expansion of benzodiazepine coverage to older adults may have been associated with an increased rate of overdose among those 69 years or younger and 80 years or older and of injury in those 80 years or older. To our knowledge, this was the first analysis to consider the association of benzodiazepine coverage policy with the risk of overdose.
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